OncoMatch/Clinical Trials/NCT03805022
Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas
Is NCT03805022 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for non-metastatic soft-tissue sarcoma.
Treatment: Doxorubicin · Ifosfamide or dacarbazine · Doxorubicin · Ifosfamide or dacarbazine · At the discretion of the investigator — The primary objective of this trial is to investigate whether the addition of 3 additional neo-adjuvant cycles of chemotherapy (doxorubicin based chemotherapy) to standard management according to the ISG-STS 10-01 study (3 cycles of neoadjuvant doxorubicin based chemotherapy + surgery +/- radiotherapy) improves the outcome of high-risk CINSARC patients with resectable soft-tissue sarcoma (STS). Primary endpoint is metastatic progression-free survival (M-PFS, after 3 years of follow-up).
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Disease stage
Grade: 23 (fnclcc)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anthracycline-based chemotherapy
Exception: no more than two cycles of neo-adjuvant anthracycline-based chemotherapy before randomization
No more than two cycle of neo-adjuvant anthracycline-based chemotherapy before randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify